格隆汇8月25日｜开源证券研报指出，健康元2025H1归母净利润7.85亿元（+1.10%）；公司2025H1毛利 率为62.21%（-1.10pct）；净利率为22.33%（+1.73pct）。2025单Q2公司归母净利润3.49亿元 （+3.72%，环比-19.88%）。公司各业务板块协同发力，丽珠集团作为发展基本盘，持续贡献稳定业 绩，丽珠单抗对公司归母净利润的影响较2024H1减亏0.62亿元，公司妥布霉素2025H1销售额同比实现 增长112%，呈现出良好的增长态势；保健品板块同比增长35%；原料药板块运营同样稳健，重点产品7- ACA价格维持良好态势，美罗培南原料药价格逐步止跌企稳。该行看好公司呼吸赛道的创新优势，维 持2025-2027归母净利润为14.63/15.68/17.15亿元，EPS为0.80/0.86/0.94元/股，当前股价对应PE为 16.1/15.0/13.7倍，维持"买入"评级。 ...

投资评级：买入（维持） | 日期 | 2025/8/22 | | --- | --- | | 当前股价(元) | 12.87 | | 一年最高最低(元) | 13.40/9.40 | | 总市值(亿元) | 235.45 | | 流通市值(亿元) | 235.45 | | 总股本(亿股) | 18.29 | | 流通股本(亿股) | 18.29 | | 近 3 个月换手率(%) | 87.15 | 健康元（600380.SH） 2025 年 08 月 25 日 股价走势图 -12% 0% 12% 24% 36% 48% 2024-08 2024-12 2025-04 健康元 沪深300 数据来源：聚源 相关研究报告 医药生物/化学制药 《单四季度收入环比回正，创新药布 局加速 — 公 司 信 息 更 新 报 告 》 -2025.4.9 《三季度业绩环比降幅收窄，创新药 业务渐入快车道—公司信息更新报 告》-2024.10.27 《产品换挡期业绩略微承压，创新转 型稳步推进—公司信息更新报告》 -2024.8.25 利润稳健增长，创新药布局加速 ——公司信息更新报告 | 余汝意（分析师） | 刘艺（联系人） | ...

Group 1 - The article discusses the new policy issued by the National Healthcare Security Administration and the National Health Commission on July 1, 2025, aimed at supporting the high-quality development of innovative drugs in China, which is expected to transform China from a "generic drug powerhouse" to an "innovative drug stronghold" [4] - The policy includes a comprehensive support system covering research and development, market access, payment, and clinical application, which is anticipated to benefit leading innovative drug companies, specialized biotech firms, and the CXO industry chain [4] Group 2 - Akole's COC project has passed safety facility acceptance review and has officially entered the stable production phase, with successful product output, indicating resolution of previous batch stability issues [5] - Xingsen Technology reported a revenue of 5.817 billion yuan for 2024, a year-on-year increase of 8.53%, but faced a net loss of 198 million yuan [6] - Kuaishou's general merchandise sales maintained high growth during the 618 shopping festival, with the launch of a new recommendation system, OneRec, expected to accelerate advertising growth in the second half of 2025 [7] - Bosideng achieved a revenue of 25.9 billion yuan for the fiscal year ending March 2025, a year-on-year increase of 11.6%, with a net profit of 3.51 billion yuan, reflecting a solid performance despite weak demand [7] - New Dairy's strategy focuses on leveraging raw milk cost advantages and improving product structure to enhance profitability, with expectations of continued raw milk benefits and increased revenue from low-temperature products [8] - Health元's respiratory product sales declined to 1.097 billion yuan in 2024, a decrease of 36.98%, but is expected to recover in 2025 as negative factors dissipate and key products gradually ramp up [9]

点击注册小程序 查看完整报告 保健品和OTC产品快速发展，驱动板块收入快速增长 24年健康元（不含丽珠集团、丽珠单抗）保健食品及OTC板块实现营业收入6.97亿元，同比增长约 53.91%。保健食品与OTC板块利用小红书、抖音、微信等新媒体内容渠道，通过达人推荐、健康科普、达 人直播带货等方式创作优质的内容触达用户，传递品牌理念，驱动品牌全渠道的销售增长。我们预计 25~26年板块发展势头良好，收入有望维持较快增速。 研发有序投入，创新转型可期 在创新药领域，公司正逐步推进"机制创新+多适应症覆盖"战略，向"抗感染+呼吸+镇痛"等多元协同方向 发展。其中：1）抗流感新药TG-1000已报产，预计2025年下半年获批上市，该新药具有较长的有效治疗 期；2）在高壁垒复杂制剂方面，沙美特罗替卡松吸入粉雾剂、丙酸氟替卡松雾化吸入用混悬液获得注册 批件，均实现国内首仿。3）在前沿靶点布局方面，TSLP单抗与IL-4R单抗均已进入Ⅱ期临床研究阶段。 在创新药加速向机制升级、适应症精准拓展演进的趋势下，公司在其呼吸系统疾病治疗主线之外，开始布 局多元化创新领域，Nav1.8作为外周神经系统疼痛信号传导的重要钠通道，具有机制 ...

2025 年 6 月 30 日 公司研究 主业转型过渡，投入创新可期 ——健康元（600380.SH）更新点评 要点 吸入制剂收入有所波动，期待妥布霉素放量。 24 年公司呼吸制剂产品销售收入 10.97 亿元，同比下降 36.98%。吸入制产品收入有所波动主要是由于：1）妥布 霉素 24 年收入主要来自于 ICU 科室销售，放量较慢；2）左沙丁胺醇受集采政 策影响收入下滑；3）23 年呼吸疾病高发形成较高基数。整体来看，24 年收入 有所波动，随着集采等负面因素消退，预计 25 年有望依托妥布霉素、舒利迭、 TG-1000 等产品的逐步放量拉动吸入制剂板块收入增长。 保健品和 OTC 产品快速发展，驱动板块收入快速增长。24 年健康元（不含丽珠 集团、丽珠单抗）保健食品及 OTC 板块实现营业收入 6.97 亿元，同比增长约 53.91%。保健食品与 OTC 板块利用小红书、抖音、微信等新媒体内容渠道，通 过达人推荐、健康科普、达人直播带货等方式创作优质的内容触达用户，传递品 牌理念，驱动品牌全渠道的销售增长。我们预计 25~26 年板块发展势头良好， 收入有望维持较快增速。 研发有序投入，创新转型可期。在 ...

Core Viewpoint - The core strategy of Haizheng Pharmaceutical is to return to the top tier of the domestic market by focusing on human medicine while developing animal medicine and health products as complementary wings [1] Group 1: Business Strategy and Development - Haizheng Pharmaceutical aims to establish a diversified development pattern with a focus on human medicine and two wings: animal medicine and health products [1] - The company has transformed its original raw material plant into a biopharmaceutical industrial park covering over 1,500 acres, encompassing high-end biopharmaceuticals, injectable and oral formulations, and export raw materials [1][3] - The company has been exporting raw materials to over 70 countries and regions since 1992, with more than 400 overseas clients, including major global pharmaceutical companies [3] Group 2: Production and Quality Control - Haizheng Pharmaceutical emphasizes the importance of high-quality raw materials, with production bases in Taizhou, Fuyang, and Nantong, featuring a complete production line with fermentation capacity of 17,000 cubic meters and synthesis capacity of 2,300 cubic meters [6] - The Fuyang base has established an international standard QEHS system and has successfully undertaken CMO orders from international giants like Merck and Codexis [6][12] - The company has passed inspections from various global regulatory bodies, including WHO, FDA, and EMA, demonstrating its commitment to quality [12] Group 3: Innovation and Product Development - The company has accelerated its transition from raw materials to formulation business, with its subsidiary Hanhui Pharmaceutical achieving significant sales growth [8][10] - Haizheng Pharmaceutical has developed its first-class innovative drug, Haibomab, which has enriched its product line [10] - The company has successfully completed technology transfers for several original products, filling gaps in domestic technology transfer for original products [10] Group 4: Animal Health Sector - The animal health sector is a key focus for Haizheng Pharmaceutical, leveraging its expertise in human medicine standards to create high-quality veterinary products [14] - The company has established a comprehensive product matrix covering pets, pigs, and ruminants, with a commitment to rigorous quality standards [15] - Haizheng Animal Health has achieved significant milestones, including the first domestic deworming drug with sales exceeding 100 million and successful market entries in countries like Vietnam [15]